Inhibition of MCL-1 to eliminate senescent cells and mitigate renal fibrosis in aristolochic acid nephropathy
Open Access
- 26 November 2025
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
The role of tubular epithelial cells (TEC) senescence in the progression from acute kidney injury (AKI) to chronic kidney disease (CKD) remains debated due to the complexity of senescent cell populations and their pro-survival mechanisms. To directly assess the contribution of TEC senescence to AKI-to-CKD progression, we employed an aristolochic acid nephropathy (AAN) mouse model. Here, we demonstrated that AAI-induced DNA damage specifically drives TEC senescence during AKI-to-CKD progression. Concomitant with the emergence of senescence, immunofluorescence staining revealed the expression of anti-apoptotic proteins, including BCL-2, BCL-xL, and MCL-1, within KIM1⁺ tubules—a marker of tubular injury. To further characterize these senescent cells, we integrated this model with snRNA-Seq data and identified a distinct population of KIM1 + senescent TEC exhibiting resistance to apoptosis through upregulation of pro-survival proteins such as MCL-1, BCL-2, and BCL-xL. To evaluate the therapeutic potential of targeting these pathways, we treated AAN mice with the MCL-1-specific inhibitor UMI-77 and the senolytic ABT-263 (targeting BCL-2/BCL-xL) during both the acute and late phases. Interestingly, only UMI-77 administration during the acute phase effectively reduced tubular senescence and mitigated fibrosis. In contrast, late-phase treatment had only marginal benefits. Notably, ABT-263 failed to eliminate senescent cells and instead exacerbated fibrosis, suggesting that while senescent TEC relies on pro-survival mechanisms to evade apoptosis, their dependency on specific anti-apoptotic proteins varies. Our study provides a high-resolution molecular framework for understanding TEC senescence and identifies MCL-1 inhibition as a precise and effective therapeutic strategy to prevent AKI-to-CKD progression, with early intervention being critical for therapeutic success.Keywords
All Related Versions
Funding Information
- Gouvernement du Canada | Canadian Institutes of Health Research (428250)
- Gouvernement du Canada | Canadian Institutes of Health Research (428250)
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (DGECR-2019-00141)
This publication has 57 references indexed in Scilit:
- Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathyKidney International, 2020
- Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerBiomedicine & Pharmacotherapy, 2020
- Acute kidney injuryThe Lancet, 2019
- Cellular senescence in the aging and diseased kidneyJournal of Cell Communication and Signaling, 2017
- Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney FibrosisTrends in Endocrinology & Metabolism, 2016
- γH2AX as a marker of DNA double strand breaks and genomic instability in human population studiesMutation Research - Reviews in Mutation Research, 2013
- A complex secretory program orchestrated by the inflammasome controls paracrine senescenceNature Cell Biology, 2013
- Critical Role of Organic Anion Transporters 1 and 3 in Kidney Accumulation and Toxicity of Aristolochic Acid IMolecular Pharmaceutics, 2011
- Senescence of Activated Stellate Cells Limits Liver FibrosisCell, 2008
- Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathyAmerican Journal of Kidney Diseases, 2003